Leerink analyst Joseph Schwartz raised the firm’s price target on Mereo BioPharma (MREO) to $8 from $6 and keeps an Outperform rating on the shares. Following the recent disclosure of longer-term data from the Phase 2 portion of the ORBIT study with setrusumab in OI, the firm is refreshing its revenue model and increasing its peak sales estimates to about $1.2B. Overall, Leerink remains positive on both Ultragenyx (RARE) and Mereo ahead of the pivotal data, potentially by year-end.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MREO:
- Mereo BioPharma’s Public Offering and Strategic Underwriter Partnership
- Biotech Alert: Searches spiking for these stocks today
- Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
- Mereo BioPharma initiated with an Outperform at Baird
- Mereo BioPharma price target raised to $7 from $6 at Needham